By: Adam Feuerstein | 08/12/14 - 05:11 PM EDT
Updated with new information from the conference call
Arrowhead Research (ARWR) just released interim results from a mid-stage study of its experimental RNA interference therapy for hepatitis B. The announcement is short on specific details but the Arrowhead drug, ARC-520, appears to have passed through its first clinical hurdle in hepatitis B patients relatively well.
Arrowhead shares closed Tuesday at $13 ahead of the ARC-520 data announcement. The stock is down 5% to $12.25 in the after-market session, reflecting some uncertainty about the results, perhaps confusion or frustration over why the company chose not to be more forthcoming with actual numbers.
I wrote a preview of the ARC-520 data recently. Here's how Arrowhead describes the ARC-520 results today:
-- Initial blinded data suggest that the magnitude of HBsAg knockdown is similar to non-human primate studies, including the chronically infected chimpanzee reported on previousl
-- Duration of knockdown appears to be substantially more sustained than in non-human primates, with patients in the 2 mg/kg group still demonstrating substantial knockdown after 8 weeks, which is the most recent time point available.
-- HBsAg levels appear to continue to decline in a number of patients at the 8 week time point in the 2 mg/kg group
10/29/14 - 09:16 AM EDT
10/29/14 - 07:30 AM EDT
10/27/14 - 11:02 AM EDT
10/22/14 - 11:52 AM EDT
10/22/14 - 08:39 AM EDT
10/30/14 - 10:45 AM EDT
10/29/14 - 09:58 AM EDT
10/29/14 - 09:40 AM EDT
10/28/14 - 11:56 AM EDT
10/28/14 - 10:58 AM EDT
David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Access the tool that DOMINATES the Russell 2000 and the S&P 500.